The P450 Oxidoreductase (POR) Rs2868177 and Cytochrome P450 (CYP) 2B6*6 Polymorphisms Contribute to the Interindividual Variability in Human CYP2B6 Activity

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2016 Jul 22

PMID 27439448

Citations 6

Authors

Li-Chen Gao

Fang-Qun Liu

Li Yang

Lin Cheng

Hai-Ying Dai

Ran Tao

Shi-Peng Cao

Di Wang

Jie Tang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate whether single-nucleotide polymorphisms (SNPs) in the P450 oxidoreductase (POR) gene were correlated with interindividual variations in cytochrome P450 (CYP) 2B6 activity.

Methods: Thirty-six healthy volunteers who tested CYP2B6 and POR polymorphisms were enrolled in the study. CYP2B6 activity was measured by bupropion hydroxylation with LC/MS/MS. The ratio of hydroxybupropion versus bupropion (AUC_hyd/AUC_bup) in terms of area under the time-concentration curve (AUC) was used to represent the CYP2B6 activity.

Results: The volunteers carrying CYP2B6*1/*1 showed a significantly higher mean AUC_hyd/ AUC_bup than those CYP2B6*1/*6 and CYP2B6*6/*6 variants (15.66 ± 1.65 vs. 9.25 ± 1.92, P = 0.008 and 15.66 ± 1.65 vs. 8.21 ± 1.74, P = 0.006, respectively). POR rs2868177 (6593 A > G) AA homozygotes showed a significantly lower mean AUC_hyd/ AUC_bup than that of POR rs2868177 AG heterozygotes or GG homozygotes (8.13 ± 1.37 vs. 12.15 ± 2.97, P = 0.005 and 8.13 ± 1.37 vs. 17.59 ± 3.25, P = 0.001, respectively). Moreover, POR rs2868177 AG heterozygotes and GG homozygotes showed a significantly increased mean AUC_hyd/AUC_bup than AA homozygotes in the CYP2B6*1/*1 and CYP2B6*6 carriers (16.40 ± 2.01 vs. 12.40 ± 1.45, P = 0.006 and 10.65 ± 1.47 vs. 6.54 ± 1.25, P = 0.004, respectively). Meanwhile, a strong correlation between the genetic variations (POR rs2868177 and CYP2B6*6) and AUC_hyd/ AUC_bup was found (P = 0.009 and P = 0.001, respectively). There was no significant difference in the mean AUC_hyd/AUC_bup among different POR *28 genotypes (P > 0.05).

Conclusion: POR rs2868177 and CYP2B6*6 variants contribute to the interindividual variability in human CYP2B6 activity, which may affect the disposition and interaction of other CYP2B6 substrate drugs.

Citing Articles

Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.

Kharasch E, Lenze E Drug Metab Dispos. 2024; 52(5):455-466.

PMID: 38467432 PMC: 11023817. DOI: 10.1124/dmd.124.001697.

Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.

Wang P, Sharma A, Montana M, Neiner A, Juriga L, Reddy K Br J Clin Pharmacol. 2022; 88(11):4881-4893.

PMID: 35538637 PMC: 10908252. DOI: 10.1111/bcp.15393.

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network.

Marok F, Fuhr L, Hanke N, Selzer D, Lehr T Pharmaceutics. 2021; 13(3).

PMID: 33806634 PMC: 8001859. DOI: 10.3390/pharmaceutics13030331.

Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon.

Fernandes M, Rodrigues J, Maronas O, Latorre-Pellicer A, Cruz R, Guerreiro J Pharmgenomics Pers Med. 2021; 14:117-133.

PMID: 33519226 PMC: 7837547. DOI: 10.2147/PGPM.S274741.

Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.

Wang P, Neiner A, Kharasch E Drug Metab Dispos. 2020; 48(6):438-445.

PMID: 32238417 PMC: 7228493. DOI: 10.1124/dmd.119.090407.

References

Gomes A, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M . Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics. 2009; 10(4):579-99. DOI: 10.2217/pgs.09.7. View

Gigon P, Gram T, GILLETTE J . Studies on the rate of reduction of hepatic microsomal cytochrome P-450 by reduced nicotinamide adenine dinucleotide phosphate: effect of drug substrates. Mol Pharmacol. 1969; 5(2):109-22. View

OLeary K, Li H, Ram P, McQuiddy P, Waxman D, Kasper C . Thyroid regulation of NADPH:cytochrome P450 oxidoreductase: identification of a thyroid-responsive element in the 5'-flank of the oxidoreductase gene. Mol Pharmacol. 1997; 52(1):46-53. DOI: 10.1124/mol.52.1.46. View

Court M, Duan S, Hesse L, Venkatakrishnan K, Greenblatt D . Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001; 94(1):110-9. DOI: 10.1097/00000542-200101000-00021. View

Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou D, Hollenberg P . Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase.... J Pharmacol Exp Ther. 2011; 338(3):803-9. PMC: 3164347. DOI: 10.1124/jpet.111.183111. View

Gao L, He Y, Tang J, Yin J, Huang Z, Liu F . Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate. PLoS One. 2013; 8(6):e62489. PMC: 3686783. DOI: 10.1371/journal.pone.0062489. View

Haroun F, Al-Shaar L, Habib R, El-Saghir N, Tfayli A, Bazarbachi A . Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer. Cancer Chemother Pharmacol. 2014; 75(1):207-14. DOI: 10.1007/s00280-014-2632-4. View

Yang G, Fu Z, Chen X, Yuan H, Yang H, Huang Y . Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. Clin Ther. 2011; 33(12):2060-70. DOI: 10.1016/j.clinthera.2011.11.004. View

Chen X, Pan L, Naranmandura H, Zeng S, Chen S . Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6. PLoS One. 2012; 7(6):e38495. PMC: 3373556. DOI: 10.1371/journal.pone.0038495. View

10.

Huang N, Agrawal V, Giacomini K, Miller W . Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A. 2008; 105(5):1733-8. PMC: 2234213. DOI: 10.1073/pnas.0711621105. View

11.

Otto D, Henderson C, Carrie D, Davey M, Gundersen T, Blomhoff R . Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic Acid homeostasis. Mol Cell Biol. 2003; 23(17):6103-16. PMC: 180925. DOI: 10.1128/MCB.23.17.6103-6116.2003. View

12.

Benowitz N, Zhu A, Tyndale R, Dempsey D, Jacob 3rd P . Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics. 2013; 23(3):135-41. PMC: 3763712. DOI: 10.1097/FPC.0b013e32835d9ab0. View

13.

Vogeler T, McClain C, Evoy K . Combination bupropion SR and varenicline for smoking cessation: a systematic review. Am J Drug Alcohol Abuse. 2016; 42(2):129-39. DOI: 10.3109/00952990.2015.1117480. View

14.

de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers D . The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011; 12(9):1281-91. DOI: 10.2217/pgs.11.77. View

15.

Lim Y, Cheng C, Chen W, Chang S, Hung D, Chen J . Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity. Arch Toxicol. 2014; 89(1):57-72. DOI: 10.1007/s00204-014-1230-x. View

16.

Gijsen V, van Schaik R, Soldin O, Soldin S, Nulman I, Koren G . P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study. Ther Drug Monit. 2013; 36(2):152-8. DOI: 10.1097/FTD.0b013e3182a3f282. View

17.

Loboz K, Gross A, Williams K, Liauw W, Day R, Blievernicht J . Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006; 80(1):75-84. DOI: 10.1016/j.clpt.2006.03.010. View

18.

Drogari E, Ragia G, Mollaki V, Elens L, van Schaik R, Manolopoulos V . POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics. 2014; 15(16):1963-72. DOI: 10.2217/pgs.14.138. View

19.

Zanger U, Klein K . Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013; 4:24. PMC: 3588594. DOI: 10.3389/fgene.2013.00024. View

20.

Chung J, Cho J, Lim H, Kim J, Yu K, Lim K . Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos. 2010; 39(1):92-7. DOI: 10.1124/dmd.110.035246. View